GLP-1 self-pay weight loss: What 100 pounds down actually requires

What did @thekristinawatts actually say?

Honestly, the video's transcript is almost entirely song lyrics, specifically the opening of Rachel Platten's "Fight Song." There are no direct medical or scientific claims in the spoken words. The substantive content lives in the caption, where Kristina describes paying $990 out of pocket for her first month of GLP-1 medication, committing to self-pay for three years, losing 100 pounds, and doing all of it without insurance coverage. That's the story we're fact-checking here, not the music.

She frames it as a personal bet: "I didn't know if it would work. I couldn't really afford it. But I knew I needed change." That's not a health claim. That's a personal narrative. And it's worth separating the two before we start evaluating anything, because a lot of GLP-1 content on TikTok blurs the line between lived experience and medical advice. This one mostly doesn't.

Does the science back this up?

The cost figure she cites is real, and the weight loss outcome she describes is biologically plausible and well-supported by clinical data. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that semaglutide 2.4 mg produced mean weight loss of 14.9% of body weight over 68 weeks. The SURMOUNT-1 trial (Jastreboff et al., 2022, NEJM) found tirzepatide produced up to 22.5% weight loss at the highest dose.

A 100-pound loss over three years is within the range of what these drugs can produce, particularly if the starting weight was high enough and the person maintained consistent use. It is not a guaranteed outcome. STEP 1 had a standard deviation wide enough to include both modest responders and very strong ones. Individual results depend on baseline weight, dose titration, adherence, diet, and genetic factors including GLP-1 receptor variants (Lotta et al., 2021, Nature Metabolism).

The $990 price point for a single month of branded semaglutide or tirzepatide without insurance is historically accurate. List prices for Wegovy have exceeded $1,300 per month at full retail, and early access programs varied widely.

What did they get wrong (or right)?

She got the cost reality right. Uninsured access to GLP-1 medications has been and remains a serious financial barrier. A 2023 analysis in Health Affairs (Chandra et al.) found that at list price, branded semaglutide would cost the average American more than 10% of median household income annually. Her $990 figure for an early prescription is consistent with that range.

She also got something tonally right that a lot of GLP-1 content gets wrong. She does not claim these drugs are easy, free of side effects, or a magic fix. She frames it as a difficult financial and personal commitment, which is a more honest representation than most of what circulates on this platform.

What's absent, and this is a gap rather than an error, is any acknowledgment that long-term outcomes after stopping GLP-1 therapy show significant weight regain. The STEP 4 trial (Rubino et al., 2021, JAMA) found that participants who discontinued semaglutide regained about two-thirds of their lost weight within a year. That context matters for anyone watching and making financial decisions based on her story.

What should you actually know?

GLP-1 receptor agonists are among the most effective pharmacological tools for weight management currently available. That is not hype, that is what the controlled trial data shows. But the evidence also shows they work best as long-term or indefinite therapy, not a short course. The financial math of self-paying for these drugs over years is significant and not discussed enough.

Access remains deeply unequal. Medicare Part D only began covering anti-obesity medications under specific circumstances after the Treat and Reduce Obesity Act provisions, and many commercial plans still exclude weight loss indications. Compounded versions of semaglutide and tirzepatide have filled some of that gap, but compounded drugs are not equivalent to brand-name products and have faced FDA scrutiny. Anyone considering self-pay GLP-1 therapy should work with a licensed clinician to determine the appropriate medication, starting dose, and monitoring plan.

Kristina's story is real and her results are plausible. But it is one data point, not a protocol. A 100-pound loss over three years with self-paid GLP-1 is a best-case outcome, not a baseline expectation.

Bottom line

This video is more personal journal entry than health advice, and it should be evaluated as such. The caption's claims about cost and weight loss are grounded in reality. The absence of medical claims is actually a point in her favor. Where it falls short is in the missing context about what happens when or if these drugs become unaffordable again, and what the long-term data says about weight regain after discontinuation. Watch it for inspiration if you want. Just don't use it as a treatment plan.